ICCM 6-K incorporates 9M 2025 results into F-3 and S-8

Rhea-AI Filing Summary

IceCure Medical Ltd. (ICCM) submitted a Form 6-K to furnish a press release covering its financial and operational results for the nine months ended September 30, 2025. The press release, dated November 19, 2025 and titled “IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025,” is attached as Exhibit 99.1.

Most of this press release, excluding its third, fourth, and fifth paragraphs, is incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8. This means the disclosed information becomes part of those registration statements from the date of this 6-K submission, unless later filings replace it.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: November 2025 (Report No. 5)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F             ☐ Form 40-F

CONTENTS

On November 19, 2025, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K. 

The press release attached herewith as Exhibit 99.1 (excluding the third, fourth, and fifth paragraphs thereof) is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660, 333-267272 and 333-290046) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release dated November 19, 2025 titled “IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ICECURE MEDICAL LTD.
Date: November 19, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

3

FAQ

What did IceCure Medical (ICCM) report in this November 2025 Form 6-K?

IceCure Medical furnished a Form 6-K to provide a press release titled “IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025.” The Form 6-K itself mainly points to this attached press release.

Which period does IceCure Medical’s latest results in this 6-K cover?

The attached press release reports IceCure Medical’s financial and operational results for the nine months ended September 30, 2025.

How is the IceCure (ICCM) press release used in its F-3 and S-8 registration statements?

The Form 6-K states that the press release in Exhibit 99.1, except for its third, fourth, and fifth paragraphs, is incorporated by reference into IceCure’s existing Form F-3 and Form S-8 registration statements, becoming part of those documents from the submission date.

Does the IceCure 6-K itself include detailed financial figures?

The Form 6-K text provided does not list specific financial figures; it instead refers investors to the attached Exhibit 99.1 press release for the detailed financial and operational results.

Which specific registration statements are affected by this IceCure Form 6-K?

The incorporated press release becomes part of IceCure’s Form F-3 registration statements with Registration Nos. 333-258660, 333-267272 and 333-290046 and its Form S-8 registration statements with Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587.

Who signed the IceCure Medical Form 6-K submitted in November 2025?

The Form 6-K was signed on behalf of IceCure Medical Ltd. by Eyal Shamir, the company’s Chief Executive Officer.